{"id":12591,"date":"2026-04-08T10:39:54","date_gmt":"2026-04-08T01:39:54","guid":{"rendered":"https:\/\/miragen.clinic\/blog\/anzupgo-cream-pharmacy-cost-690000-krw-can-it-be-used-for-atopic-dermatitis\/"},"modified":"2026-07-02T00:42:29","modified_gmt":"2026-07-01T15:42:29","slug":"anzupgo-cream-pharmacy-cost-690000-krw-can-it-be-used-for-atopic-dermatitis","status":"publish","type":"post","link":"https:\/\/miragen.clinic\/en\/blog\/anzupgo-cream-pharmacy-cost-690000-krw-can-it-be-used-for-atopic-dermatitis\/","title":{"rendered":"Anzupgo Cream, Pharmacy Cost 690,000 KRW | Can It Be Used for Atopic Dermatitis?"},"content":{"rendered":"\n<div class=\"wp-block-group alignwide has-global-padding is-layout-constrained wp-container-core-group-is-layout-134ed493 wp-block-group-is-layout-constrained\">\n<div class=\"wp-block-group alignwide has-global-padding is-layout-constrained wp-container-core-group-is-layout-0958e68c wp-block-group-is-layout-constrained\">\n<p class=\"wp-block-paragraph\">Anzupgo Cream, Korea&#8217;s first topical JAK inhibitor, was launched in March 2026. Interest is high among patients with atopic dermatitis. Since oral JAK inhibitors are already used for atopic dermatitis, there is an expectation that a topical version might also be possible.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">To start with the conclusion, the only currently approved indication for Anzupgo is chronic hand eczema. It cannot be used for atopic dermatitis yet. However, it is not a meaningless drug for atopic patients. We have summarized what kind of drug it is, why it is attracting attention, and what the future holds.   <\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" width=\"1024\" height=\"576\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/04\/anzupgo-delgocitinib-cream-tube.jpg\" alt=\"A tube of Anzupgo Cream (delgocitinib), a treatment for chronic hand eczema launched as a non-reimbursable item in Korea in March 2026; it is the world's first non-steroidal JAK inhibitor cream approved for hand eczema.\" class=\"wp-image-10149\" title=\"Anzupgo Cream (delgocitinib) Product\"\/><\/figure>\n\n\n\n<div class=\"wp-block-rank-math-toc-block has-custom-color-5-color has-custom-color-2-background-color has-text-color has-background has-link-color wp-elements-c10fdd73a5276ac43159b29cb3e5f8eb\" style=\"padding-top:var(--wp--preset--spacing--superbspacing-xsmall);padding-right:0;padding-bottom:var(--wp--preset--spacing--superbspacing-xsmall);padding-left:0\" id=\"rank-math-toc\"><h2>\ubaa9\ucc28<\/h2><nav><ul><li><a href=\"#sec-1\">Anzupgo Cream Summary<\/a><\/li><li><a href=\"#sec-2\">What is a JAK Inhibitor?<\/a><\/li><li><a href=\"#sec-3\">Numbers from Clinical Trials<\/a><\/li><li><a href=\"#sec-4\">Comparison with Existing Treatments<\/a><\/li><li><a href=\"#sec-5\">Prescription \u00b7 Insurance \u00b7 Price<\/a><\/li><li><a href=\"#sec-faq\">Frequently Asked Questions<\/a><\/li><\/ul><\/nav><\/div>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-1\">Anzupgo Cream Summary<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table class=\"has-fixed-layout\"><tbody><tr><td><strong>Ingredient Name<\/strong><\/td><td>Delgocitinib<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Topical JAK inhibitor (non-steroidal)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Moderate to severe chronic hand eczema (when steroids are unresponsive or inappropriate)<\/td><\/tr><tr><td><strong>Atopic Dermatitis Indication<\/strong><\/td><td>Not approved in Korea \u2014 Approved for atopic dermatitis in Japan since 2020<\/td><\/tr><tr><td><strong>MFDS Approval<\/strong><\/td><td>September 2025<\/td><\/tr><tr><td><strong>Launch<\/strong><\/td><td>March 2026 (Non-reimbursable)<\/td><\/tr><tr><td><strong>Health Insurance<\/strong><\/td><td>Not listed \u2014 Full patient out-of-pocket cost<\/td><\/tr><tr><td><strong>Usage<\/strong><\/td><td>Apply a thin layer twice daily, at 12-hour intervals<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-2\">What is a JAK Inhibitor?<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">When skin inflammation occurs, immune cells exchange signals. JAK is an enzyme that plays a key role in this signal transduction process. There are four types of JAK, and Anzupgo Cream blocks all four. It works by reducing the signal transduction itself to calm the inflammatory response.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40658334\/\" target=\"_blank\" rel=\"noopener\">1<\/a><\/sup>   <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">When applied, most of it acts on the skin, and very little is absorbed into the blood. Therefore, the risk of systemic side effects concerned with oral JAK inhibitors\u2014such as increased risk of infection or blood clots\u2014is much lower.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40658334\/\" target=\"_blank\" rel=\"noopener\">1<\/a><\/sup> <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The biggest difference from <a href=\"https:\/\/miragen.clinic\/en\/topical-steroids\/\" data-type=\"page\" data-id=\"6430\">topical steroids<\/a> is skin atrophy. Long-term use of steroids can thin the skin, but Anzupgo Cream carries no such risk. No skin atrophy was reported even in clinical trials using it for up to 52 weeks.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40081663\/\" target=\"_blank\" rel=\"noopener\">2<\/a><\/sup>  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anzupgo Cream is the world&#8217;s first topical medication specifically approved for chronic hand eczema.<\/p>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/06\/jak-pathway-ruxolitinib-mechanism-v2-EN.png\" alt=\"A medical illustration showing the JAK pathway inhibition, the mechanism of action for Anzupgo Cream, which reduces itching and inflammation in hand eczema and atopic dermatitis by blocking inflammatory signal transduction in immune cells.\" class=\"wp-image-10085\" title=\"JAK Pathway Inhibition Mechanism\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>The reason it is attracting attention from doctors and patients treating atopic dermatitis is simple.<\/strong> This is because atopic dermatitis also creates inflammation through the same JAK pathway. In fact, delgocitinib has been approved and used for atopic dermatitis indications in Japan since 2020. Since oral JAK inhibitors (Rinvoq, Cibinqo, etc.) are already being prescribed for atopic dermatitis in Korea, it is natural to expect that a topical JAK inhibitor could also be used.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, whether or when Anzupgo&#8217;s indication will be expanded to atopic dermatitis in Korea has not yet been determined. Currently, it can only be prescribed for chronic hand eczema. <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">The Only Topical JAK Inhibitor in Korea<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Interest in topical JAK inhibitors existed even before Anzupgo. A JAK inhibitor cream called Opzelura is approved for atopic dermatitis and vitiligo in the US and Europe, and some patients are purchasing and using Rutinib ointment, which has the same ingredients, from overseas. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">However, neither Opzelura nor Rutinib ointment is approved in Korea. Overseas direct-purchase products are used without a prescription, lack verification, and it is difficult to find a doctor with experience with these drugs if a problem arises. The <a href=\"https:\/\/miragen.clinic\/blog\/%eb%a3%a8%ed%8b%b0%eb%8b%99-%ec%97%b0%ea%b3%a0-%ec%98%b5%ec%a0%a4%eb%a3%a8%eb%9d%bc\/\" data-type=\"post\" data-id=\"10080\">difference between Rutinib ointment and Opzelura<\/a> is covered in detail in a separate post. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Anzupgo Cream is the only topical JAK inhibitor officially approved and launched in Korea. Although its indication is limited to chronic hand eczema and it is currently non-reimbursable, meaning the patient must bear the full cost, it is currently the safest option as a verified product launched through official channels. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-3\">Numbers from Clinical Trials<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<p class=\"wp-block-paragraph\">These are the results of two Phase 3 clinical trials that served as the basis for approval. 960 patients with moderate to severe chronic hand eczema participated.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39033766\/\" target=\"_blank\" rel=\"noopener\">3<\/a><\/sup> <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">Percentage of patients with clear or almost clear skin after 16 weeks of use<\/h3>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table class=\"has-fixed-layout\"><thead><tr><th><\/th><th class=\"has-text-align-left\" data-align=\"left\">Anzupgo<\/th><th class=\"has-text-align-left\" data-align=\"left\">Placebo<\/th><\/tr><\/thead><tbody><tr><td>DELTA 1 (325 people vs 162 people)<\/td><td class=\"has-text-align-left\" data-align=\"left\">20%<\/td><td class=\"has-text-align-left\" data-align=\"left\">10%<\/td><\/tr><tr><td>DELTA 2 (313 people vs 159 people)<\/td><td class=\"has-text-align-left\" data-align=\"left\">29%<\/td><td class=\"has-text-align-left\" data-align=\"left\">7%<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<figure class=\"wp-block-image aligncenter size-large\"><img decoding=\"async\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/06\/anzupgo-delta-trial-results-EN.jpeg\" alt=\"An infographic comparing the 16-week results of the Anzupgo Cream Phase 3 clinical trials DELTA 1 and DELTA 2, showing that the rate of skin clearing was 2 to 4 times higher with Anzupgo than with placebo, and itching decreased from day 1.\" class=\"wp-image-10161\" title=\"Comparison of Anzupgo Cream DELTA Clinical Trial Results\"\/><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The figures of 20\u201330% might seem low, but it is because the strict criteria of &#8220;completely clear or almost clear&#8221; were used. Based on the criteria of 75% or more improvement, a significant number of patients experience meaningful improvement. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In particular, itching was significantly reduced compared to placebo from the first day of application, and pain from the third day. Hand eczema is a condition that makes daily life difficult due to itching and pain, and a difference is quickly seen in these areas.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39033766\/\" target=\"_blank\" rel=\"noopener\">3<\/a><\/sup> <\/p>\n\n\n\n<h3 class=\"wp-block-heading\">What about long-term use?<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">Efficacy was maintained in clinical trials extended up to 52 weeks. The group that switched to Anzupgo after using a placebo for 16 weeks also reached a level similar to existing users. The rate of 75% or more improvement was 51.5%.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40081663\/\" target=\"_blank\" rel=\"noopener\">2<\/a><\/sup>  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\">In an analysis synthesizing several clinical trials, Anzupgo Cream showed a treatment success rate approximately 3 times higher than placebo.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41891530\/\" target=\"_blank\" rel=\"noopener\">4<\/a><\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-4\">Comparison with Existing Treatments<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<figure class=\"wp-block-table is-style-stripes\"><table class=\"has-fixed-layout\"><thead><tr><th><\/th><th class=\"has-text-align-left\" data-align=\"left\">Steroids<\/th><th class=\"has-text-align-left\" data-align=\"left\">Protopic \u00b7 Elidel<\/th><th class=\"has-text-align-left\" data-align=\"left\">Anzupgo<\/th><\/tr><\/thead><tbody><tr><td><strong>Mechanism of Action<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">Broad-spectrum inflammation suppression<\/td><td class=\"has-text-align-left\" data-align=\"left\">Calcineurin inhibition<\/td><td class=\"has-text-align-left\" data-align=\"left\">JAK inhibition<\/td><\/tr><tr><td><strong>Skin Atrophy<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">Risk with long-term use<\/td><td class=\"has-text-align-left\" data-align=\"left\">None<\/td><td class=\"has-text-align-left\" data-align=\"left\">None<\/td><\/tr><tr><td><strong>Hand Eczema Approval<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">None<\/td><td class=\"has-text-align-left\" data-align=\"left\">None<\/td><td class=\"has-text-align-left\" data-align=\"left\">Yes (First)<\/td><\/tr><tr><td><strong>Health Insurance<\/strong><\/td><td class=\"has-text-align-left\" data-align=\"left\">Applied<\/td><td class=\"has-text-align-left\" data-align=\"left\">Applied<\/td><td class=\"has-text-align-left\" data-align=\"left\">Not listed<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">In a comprehensive analysis of 291 clinical trials by the Cochrane research team, the efficacy of Anzupgo Cream was at a level similar to high-potency topical steroids and tacrolimus 0.1%.<sup><a style=\"color: inherit;\" href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39105474\/\" target=\"_blank\" rel=\"noopener\">5<\/a><\/sup><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Therefore, for chronic dermatitis patients whose response to <a href=\"https:\/\/miragen.clinic\/en\/protopic\/\" data-type=\"page\" data-id=\"6419\">Protopic<\/a> 0.1% is insufficient, Anzupgo Cream could be considered.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"sec-5\">Prescription \u00b7 Insurance \u00b7 Price<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-wide\"\/>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Prescription:<\/strong> It can be prescribed now. However, the approved indication is &#8220;moderate to severe chronic hand eczema that does not respond to topical steroids or for which steroids are not appropriate.&#8221; Therefore, a history of trying steroids first is required.  <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Insurance:<\/strong> Since it is not covered by health insurance, the patient must bear the full cost. The timing for health insurance coverage is undecided, and even if it becomes covered, it is likely to be applied restrictively only to cases that do not respond to existing treatments. <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Price:<\/strong> The pharmacy cost for one 60g tube is approximately 690,000 KRW. Since it is non-reimbursable, the retail price may vary by pharmacy, and it is a high price. If you purchase <a href=\"https:\/\/miragen.clinic\/blog\/%eb%a3%a8%ed%8b%b0%eb%8b%99-%ec%97%b0%ea%b3%a0-%ec%98%b5%ec%a0%a4%eb%a3%a8%eb%9d%bc\/\" data-type=\"post\" data-id=\"10080\">Rutinib ointment<\/a> from overseas, it is about 180,000 KRW for 30g, which is about half the price per gram of Anzupgo Cream. However, if you must use a topical JAK inhibitor, Anzupgo Cream seems better despite the price difference. This is because Rutinib ointment is not a product from the original developer with FDA approval and cannot be considered verified.    <\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity is-style-dots\"\/>\n\n\n\n<h3 class=\"wp-block-heading\">References<\/h3>\n\n\n\n<ol class=\"wp-block-list has-custom-color-5-color has-text-color has-link-color has-superbfont-xxsmall-font-size wp-elements-7802f26824d3debf18e87ab536f6af5f\">\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40658334\/\" target=\"_blank\" rel=\"noopener\"><em>McGuigan C et al. Delgocitinib 20 mg\/g Cream: A Review in Chronic Hand Eczema. Drugs.   2025.<\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/40081663\/\" target=\"_blank\" rel=\"noopener\"><em>Gooderham M et al. Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema. J Am Acad Dermatol. 2025;93:95\u2013103.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39033766\/\" target=\"_blank\" rel=\"noopener\"><em>Bissonnette R et al. Efficacy and safety of delgocitinib cream in adults with moderate to severe chronic hand eczema (DELTA 1 and DELTA 2). Lancet. 2024;404:461\u2013473.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/41891530\/\" target=\"_blank\" rel=\"noopener\"><em>de Moraes-Souza R et al. Efficacy and Safety of Topical Delgocitinib for Chronic Hand Eczema: A Systematic Review and Meta-Analysis. Exp Dermatol. 2026;35:e70242.   <\/em><\/a><\/li>\n\n\n\n<li><a href=\"https:\/\/pubmed.ncbi.nlm.nih.gov\/39105474\/\" target=\"_blank\" rel=\"noopener\"><em>Lax SJ et al. Topical anti-inflammatory treatments for eczema: network meta-analysis. Cochrane Database Syst Rev. 2024;8:CD015064.<\/em><\/a><\/li>\n<\/ol>\n\n\n\n<div class=\"wp-block-group alignwide is-style-superbaddons-card has-custom-color-2-background-color has-background has-global-padding is-layout-constrained wp-block-group-is-layout-constrained\" style=\"border-style:none;border-width:0px;border-top-left-radius:16px;border-top-right-radius:16px;border-bottom-left-radius:16px;border-bottom-right-radius:16px\">\n<h2 class=\"wp-block-heading has-custom-color-4-color has-text-color has-link-color wp-elements-fec4206f5af5888537ae11aefd49af22\" id=\"sec-faq\">Frequently Asked Questions<\/h2>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-color-5-color has-alpha-channel-opacity has-custom-color-5-background-color has-background is-style-wide\" style=\"margin-top:var(--wp--preset--spacing--superbspacing-xsmall);margin-bottom:var(--wp--preset--spacing--superbspacing-xsmall)\"\/>\n\n\n<div id=\"rank-math-faq\" class=\"rank-math-block\">\n<div class=\"rank-math-list \">\n<div id=\"faq-1\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">Can Anzupgo be prescribed for atopic dermatitis?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Currently, the approved indication in Korea is chronic hand eczema. It cannot be prescribed for atopic dermatitis. It has been used for atopic dermatitis indications in Japan since 2020, and while an expansion of indications is expected in Korea, the timing is undecided.  <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-2\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">What is the difference between oral JAK inhibitors and topical Anzupgo?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>Oral JAK inhibitors like Rinvoq and Cibinqo act systemically and are used for moderate to severe atopic dermatitis. Anzupgo is a cream, so it acts only on the applied area and has almost no systemic absorption, reducing the burden of systemic side effects. However, its current indication is limited to chronic hand eczema.  <\/p>\n\n<\/div>\n<\/div>\n<div id=\"faq-3\" class=\"rank-math-list-item\">\n<h3 class=\"rank-math-question \">When will insurance coverage be available?<\/h3>\n<div class=\"rank-math-answer \">\n\n<p>It is known that the health insurance reimbursement review is underway, but the listing date has not been confirmed. Currently, it is a non-reimbursable item with the patient bearing the full cost, at a level of approximately 690,000 KRW for 60g. <\/p>\n\n<\/div>\n<\/div>\n<\/div>\n<\/div><\/div>\n\n\n\n<div class=\"wp-block-group has-custom-color-2-background-color has-background has-global-padding is-layout-constrained wp-container-core-group-is-layout-ffa602f6 wp-block-group-is-layout-constrained\" style=\"border-top-left-radius:16px;border-top-right-radius:16px;border-bottom-left-radius:16px;border-bottom-right-radius:16px;padding-top:0;padding-right:0;padding-bottom:0;padding-left:0\">\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-8c970b27 wp-block-columns-is-layout-flex\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:40%\">\n<figure class=\"wp-block-image size-full\" style=\"margin-right:0;margin-left:0\"><img decoding=\"async\" width=\"600\" height=\"600\" src=\"https:\/\/miragen.clinic\/wp-content\/uploads\/2026\/01\/doctor-han-namecard-profile.png\" alt=\"\" class=\"wp-image-3537\"\/><\/figure>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-vertically-aligned-center is-layout-flow wp-block-column-is-layout-flow\" style=\"padding-top:var(--wp--preset--spacing--superbspacing-small);padding-right:var(--wp--preset--spacing--superbspacing-small);padding-bottom:var(--wp--preset--spacing--superbspacing-small);padding-left:var(--wp--preset--spacing--superbspacing-small);flex-basis:60%\">\n<div class=\"wp-block-group has-global-padding is-layout-constrained wp-container-core-group-is-layout-dec8e639 wp-block-group-is-layout-constrained\" style=\"padding-top:0;padding-right:0;padding-bottom:0;padding-left:0\">\n<p class=\"has-custom-color-3-color has-text-color has-link-color has-superbfont-large-font-size wp-elements-9a43ded5a855c918bdce811724da93c4 wp-block-paragraph\" style=\"font-style:normal;font-weight:600\">We treat atopic dermatitis, rosacea, and seborrheic dermatitis.<br\/><\/p>\n\n\n\n<p class=\"has-custom-color-5-color has-text-color has-link-color has-superbfont-small-font-size wp-elements-b0ed9896cd87c4dc29ef35753e45458c wp-block-paragraph\">Thanks to the valuable reviews you have shared in the community, many of you visit us even from far away.<br\/>We will repay you with sincere, attentive care.<\/p>\n\n\n\n<hr class=\"wp-block-separator has-text-color has-custom-color-6-color has-alpha-channel-opacity has-custom-color-6-background-color has-background is-style-wide\"\/>\n\n\n\n<div class=\"wp-block-columns is-layout-flex wp-container-core-columns-is-layout-e1e686a6 wp-block-columns-is-layout-flex\" style=\"padding-top:0;padding-bottom:0\">\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:33.33%\">\n<div class=\"wp-block-group is-vertical is-layout-flex wp-container-core-group-is-layout-19afc361 wp-block-group-is-layout-flex\">\n<p class=\"has-custom-color-3-color has-text-color has-link-color has-superbfont-small-font-size wp-elements-5046f5cbf2504632740a9221c469d447 wp-block-paragraph\"><strong>DK Han<\/strong><\/p>\n\n\n\n<p class=\"has-custom-color-5-color has-text-color has-link-color has-superbfont-xsmall-font-size wp-elements-f628b1a898e0079d43059baed3da5249 wp-block-paragraph\">Chief Director, MIRAGEN Clinic<\/p>\n<\/div>\n<\/div>\n\n\n\n<div class=\"wp-block-column is-layout-flow wp-block-column-is-layout-flow\" style=\"flex-basis:66.66%\">\n<p class=\"has-custom-color-5-color has-text-color has-link-color has-superbfont-xsmall-font-size wp-elements-0a159b55280bf6519f7c0f2e7a7ab305 wp-block-paragraph\">Graduate of University of Michigan, Ross School of Business<br\/>Graduate of Chungnam National University School of Medicine<br\/>(Former) Representative Director of Ewha Phoenix Rehabilitation Hospital<br\/>(Current) Representative Director of MIRAGEN Clinic<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Anzupgo Cream (delgocitinib) is Korea&#8217;s first topical JAK inhibitor. We have summarized its approval for chronic hand eczema, prospects for atopic dermatitis indications, clinical trial results, the 690,000 KRW price for 60g, and insurance status. <\/p>\n","protected":false},"author":1,"featured_media":12592,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_miragen_jsonld":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-12591","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-1"],"_links":{"self":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts\/12591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/comments?post=12591"}],"version-history":[{"count":2,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts\/12591\/revisions"}],"predecessor-version":[{"id":12594,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/posts\/12591\/revisions\/12594"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/media\/12592"}],"wp:attachment":[{"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/media?parent=12591"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/categories?post=12591"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/miragen.clinic\/en\/wp-json\/wp\/v2\/tags?post=12591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}